Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2014.635 | Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world | Dr. WONG Raymond Siu Ming |
| 2017.002 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2014.269 | A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndrome (MDS) | Dr. WONG Raymond Siu Ming |
| 2015.010 | The hepato-protective effects of umbilical cord-derived stem cell on acetaminophen induced liver injury. | Dr. WONG Raymond Siu Ming |
| 2015.147 | A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2 |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2013.608 | An open-label, single-arm, Phase Ib/II study of AEB071 (a protein kinase C inhibitor) and everolimus (mTOR inhibitor) in patients with CD79-mutant or ABC subtype diffuse large B-cell lymphoma | Dr. WONG Raymond Siu Ming |
| 2017.267 | A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4 |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2016.178 | A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects with Previously-Treated Indolent Non-Hodgkin Lymphoma |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2020.692 | A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOMITANT JAK2 INHIBITOR THERAPY AND WHO REQUIRE RED BLOOD CELL TRANSFUSIONS The “INDEPENDENCE” Trial |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2020.576 | A Study to Describe the Real-world Use of Dasatinib Treatment for Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukaemia (CML) | Dr. WONG Raymond Siu Ming |
| 2020.156 | A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.229 | Real-world Evidence of the Use of Carfilzomib Among Patients With Relapsed/Refractory Multiple Myeloma in Asia Pacific |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.512 | A retrospective analysis of risk factors and outcomes of cancer-associated venous thromboembolism in Chinese patients | Dr. WONG Raymond Siu Ming |
| 2019.481 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF REGN3918 IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Dr. WONG Raymond Siu Ming |
| 2019.286 | A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2018.471 | An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of PEGCETACOPLAN in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.158 | An Open-Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor-Naive or Have Not Recently Received Complement Inhibitor Therapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.160 | A Phase 3, Multicenter, Open-Label, Single-Arm Study to Confirm the Safety and Efficacy of Zilucoplan in Treatment-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.225 | A phase 3, multi-center, open-label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2010.159 | A longitudinal 2-year bone marrow study of eltrombopag olamine (SB-497115-GR) in previously treated adults, with chronic immune (idiopathic) thrombocytopenic purpura(ITP) | Dr. WONG Raymond Siu Ming |
| 2016.463 | A Multi-centre, Observational Study of Patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.347 | Molecular study of myelofibrosis with next generation sequencing to identify prognostic markers and to evaluate applicability of prognostic models in Chinese population |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.567 | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in study participants with persistent or chronic primary immune thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.493 | A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.641 | A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.392 | Molecular study of essential thrombocythaemia with next generation sequencing to identify prognostic markers in Chinese population | Dr. WONG Raymond Siu Ming |
| 2022.652 | A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations (BELLWAVE-008) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2012.406 | A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | Dr. Wong Raymond Siu-Ming |
| 2009.087 | Peer Leaders Accelated Training Initiative to Unlash Potential of mentorship (PLATINUM) Program: A feasibility study on a train-the-trainer course on peer support for people with type 2 diabetes | Ms WONG Rebecca Y M |
| 2016.391 | A study to evaluate the effectiveness of a structured patient education on patient discharge in Department of Medicine and Therapeutics, Prince of Wales Hospital |
Ms. WONG Rebecca Yee Man 黃綺文 |
| 2017.447 | Vibration Therapy as a Rehabilitation Intervention for Postural Training and Fall Prevention after Distal Radius Fracture in Elderly Patients: A Randomized Controlled Trial | Dr. WONG Ronald Man Yeung |
| 2021.488 | Detection of Clinically Silent Vertebral Fractures with Vertebral Fracture Assessment on a Fracture Liaison Service in a Chinese Population |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2021.622 | Fracture Liaison Services For Osteoporotic Fracture |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2023.401 | RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: A Pragmatic, Randomized Double-blind, Active-Controlled Trial | Prof. WONG Ronald Man Yeung |
| 2021.478 | A multicentre retrospective study on the clinical and radiological features, and outcome of surgical treatment in Atypical Femoral Fractures in Hong Kong |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2022.555 | RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial | Prof. WONG Ronald Man Yeung |
| 2022.256 | Artificial Intelligence in Detection of Vertebral Compression Fracture |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2022.079 | Sarcopenia in Hip Fracture Patients |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2021.384 | Prevalence of Ostersarcopenia in Fragility Fracture Patients |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2018.584 | Vibration Therapy as an Intervention for Enhancing Trochanteric Hip Fracture Healing in Elderly Patients: A Randomized Double-Blinded, Placebo-Controlled Clinical Trial |
Dr. WONG Ronald Man Yeung 黄文揚 |
| 2019.202 | Imminent Fracture in Hong Kong | Prof. WONG Ronald Man Yeung |
| 2019.227 | Prevention of Imminent Fragility Fractures: A Call to Action in Hong Kong | Prof WONG Ronald Man Yeung |
| 2018.415 | Vibration Therapy as a Rehabilitation Intervention for Postural Training and Fall Prevention after Distal Radius Fracture in Elderly Patients: A Randomized Controlled Trial | Dr. WONG Ronald Man Yeung |
| 2021.008 | The Composition of Gut Microbiota in Patients with Sarcopenia and Osteoporosis |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2018.354 | Promotion in the Early Management of Knee Osteoarthritis in Community-dwelling Elderlies – “A New Community-based Vibration Therapy Program to Prevent Falls, Strengthen Muscle and Relief Pain” |
Dr. WONG Ronald Man Yeung 黃文揚 |
| 2018.192 | Necrotizing fasciitis induced by Vibrio Vulnificus in Patients without Marine Contact in Hong Kong | Dr. WONG Ronald Man Yeung |
| 2019.579 | Comparative Persistence With Prolia® and Weekly Alendronate in 6 Asia-Pacific countries: a Prospective Observational Study |
Dr. WONG Ronald Man Yeung 黃文揚 |
| 2020.290 | Biodegradable Magnesium Screws in Elbow Fracture Fixation: Clinical Case Series |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2018.602 | Promoting to tackle sarcopenia by combined elastic-band resistance exercise or vibration treatment with hydroxylmethylbutyrate (HMB) supplement for older people | Prof. WONG Ronald Man Yeung |
| 2022.343 | Effectiveness of a New Approach in Stroke Upper Limb Rehabilitation with Shortened Fugl-Meyer Assessment Classification: A Randomized Controlled Trial |
Miss WONG Sally Hiu Lam 黃曉嵐 |
Page 235 of 262.